Bottom line
How much do FHLC and JDOC overlap?
63% of their top holdings overlap by weight. 15 securities appear in both funds' top 25, making up 56.4% of FHLC's assets and 55.8% of JDOC's. They share a meaningful core but differ in the rest of the portfolio.
FHLC holds far more positions (337 vs 61), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings FHLC and JDOC have in common
| Holding | % of FHLC | % of JDOC | Overlap |
|---|---|---|---|
| Eli Lilly & Co | 13.35% | 7.76% | 7.76% |
| Johnson & Johnson | 8.93% | 4.82% | 4.82% |
| AbbVie Inc | 6.42% | 7.85% | 6.42% |
| UnitedHealth Group Inc | 5.44% | 5.85% | 5.44% |
| Merck & Co Inc | 4.66% | 4.82% | 4.66% |
| Thermo Fisher Scientific Inc | 3.09% | 3.73% | 3.09% |
| Abbott Laboratories | 2.66% | 3.11% | 2.66% |
| Bristol-Myers Squibb Co | 1.93% | 3.57% | 1.93% |
| CVS Health Corp | 1.92% | 2.83% | 1.92% |
| Intuitive Surgical Inc | 1.82% | 1.93% | 1.82% |
| Danaher Corp | 1.80% | 2.16% | 1.80% |
| Stryker Corp | 1.62% | 2.23% | 1.62% |
| Regeneron Pharmaceuticals Inc | 1.15% | 1.60% | 1.15% |
| Cencora Inc | 0.83% | 2.07% | 0.83% |
| Cardinal Health Inc | 0.78% | 1.51% | 0.78% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in FHLC
- Amgen Inc — 3.00%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
- Vertex Pharmaceuticals Inc — 1.76%
- Medtronic PLC — 1.59%
- McKesson Corp — 1.52%
- Elevance Health Inc — 1.19%
- Cigna Group/The — 1.06%
- Boston Scientific Corp — 1.00%
- HCA Healthcare Inc — 0.91%
Only in JDOC
- AstraZeneca plc — 3.76%
- Roche Holding AG — 2.82%
- Novo Nordisk A/S — 2.61%
- GSK plc — 2.47%
- Argenx SE — 2.06%
- Edwards Lifesciences Corp. — 1.73%
- IQVIA Holdings, Inc. — 1.71%
- Teva Pharmaceutical Industries Ltd. — 1.60%
- Novartis AG — 1.60%
- Biogen, Inc. — 1.56%
Asset mix
| Asset type | FHLC | JDOC |
|---|---|---|
| Stocks | 99.7% | 99.2% |
| Cash & short-term funds | 0.2% | — |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)
Country mix
| Country | FHLC | JDOC |
|---|---|---|
| US | 96.5% | 75.2% |
| GB | 0.5% | 6.2% |
| CH | 0.1% | 4.4% |
| DK | — | 4.0% |
| JP | — | 2.5% |
| NL | 0.1% | 2.4% |
| IE | 2.2% | 0.4% |
| DE | — | 1.9% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do FHLC and JDOC overlap?
What stocks do FHLC and JDOC have in common?
Should I own both FHLC and JDOC?
Which holds more stocks, FHLC or JDOC?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.